RO27-3225 TFA | CAS#1373926-49-8 | Melanocortin type 4 receptor agonist

MedKoo Cat#: 571366 | Name: RO27-3225 TFA

Description:

WARNING: This product is for research use only, not for human or veterinary use.

RO27-3225, also known as RO273225 is a melanocortin type 4 receptor agonist with EC50 = 1 nM. It may alleviate intestinal dysfuntion and brain damage. It has been investigated for an anti-obesity medication. Ro 27-3225 shows some activity at the MC1 receptor. Ro 27-3225 reverses hemorrhagic shock, reduces multiple organ damage, and improves survival.

Chemical Structure

RO27-3225 TFA

CAS#1373926-49-8 (TFA)

Theoretical Analysis

MedKoo Cat#: 571366

Name: RO27-3225 TFA

CAS#: 1373926-49-8 (TFA)

Chemical Formula: C41H53F3N12O8

Exact Mass:

Molecular Weight: 898.95

Elemental Analysis: C, 54.78; H, 5.94; F, 6.34; N, 18.70; O, 14.24

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

274682-89-2 (free base) 1057258-86-2 (free base isomer) 1373926-49-8 (TFA) 1051970-60-5 (3 TFA)

Synonym

RO27-3225 TFA; RO273225; RO 273225; RO-273225; RO27-3225; RO27 3225; Butir-His-D-Phe-Arg-Trp-Sar-NH2; CID 9962372;

IUPAC/Chemical Name

(S)-N-((S)-1-((2-amino-2-oxoethyl)(methyl)amino)-3-(1H-indol-3-yl)-1-oxopropan-2-yl)-2-((S)-2-((S)-2-butyramido-3-(1H-imidazol-4-yl)propanamido)-3-phenylpropanamido)-5-guanidinopentanamide trifluoroacetic acid

InChi Key

XBNXUPIBUGBMCO-WYDLTDSDSA-N

InChi Code

InChI=1S/C39H52N12O6.C2HF3O2/c1-3-10-34(53)47-31(19-26-21-43-23-46-26)37(56)49-30(17-24-11-5-4-6-12-24)36(55)48-29(15-9-16-44-39(41)42)35(54)50-32(38(57)51(2)22-33(40)52)18-25-20-45-28-14-8-7-13-27(25)28;3-2(4,5)1(6)7/h4-8,11-14,20-21,23,29-32,45H,3,9-10,15-19,22H2,1-2H3,(H2,40,52)(H,43,46)(H,47,53)(H,48,55)(H,49,56)(H,50,54)(H4,41,42,44);(H,6,7)/t29-,30-,31-,32-;/m0./s1

SMILES Code

O=C(O)C(F)(F)F.O=C(N[C@@H](CC1=CNC2=C1C=CC=C2)C(N(CC(N)=O)C)=O)[C@@H](NC([C@@H](NC([C@@H](NC(CCC)=O)CC3=CNC=N3)=O)CC4=CC=CC=C4)=O)CCCNC(N)=N

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

	Solvent	mg/mL	mM
Solubility
	Soluble in DMSO	0.0	100.00

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 898.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Liu D, Zhang HG, Chang MT, Li Y, Zhang LY. Melanocortin-4 receptor agonists alleviate intestinal dysfunction in secondary intra-abdominal hypertension rat model. J Surg Res. 2015 May 1;195(1):263-70. doi: 10.1016/j.jss.2015.01.007. Epub 2015 Jan 13. PubMed PMID: 25659615. 2: Liu D, Zhang HG, Zhao ZA, Chang MT, Li Y, Yu J, Zhang Y, Zhang LY. Melanocortin MC4 receptor agonists alleviate brain damage in abdominal compartment syndrome in the rat. Neuropeptides. 2015 Feb;49:55-61. doi: 10.1016/j.npep.2014.12.003. Epub 2015 Jan 7. PubMed PMID: 25616531. 3: Li H, Qiu D, Gao Q, Wang H, Sun M. [Selectively activating melanocortin 4 receptor acts against rat sepsis-induced acute liver injury via HMGB1/TLR4/NF-κB signaling pathway]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016 Aug;32(8):1055-9. Chinese. PubMed PMID: 27412936. 4: Zheng Y, McPherson K, Reid P, Smith PF. The anti-inflammatory selective melanocortin receptor subtype 4 agonist, RO27-3225, fails to prevent acoustic trauma-induced tinnitus in rats. Eur J Pharmacol. 2015 Aug 15;761:206-10. doi: 10.1016/j.ejphar.2015.05.007. Epub 2015 May 12. PubMed PMID: 25977231. 5: Bhorkar AA, Dandekar MP, Nakhate KT, Subhedar NK, Kokare DM. Involvement of the central melanocortin system in the effects of caffeine on anxiety-like behavior in mice. Life Sci. 2014 Jan 30;95(2):72-80. doi: 10.1016/j.lfs.2013.12.014. Epub 2013 Dec 19. PubMed PMID: 24361398. 6: Lonati C, Sordi A, Giuliani D, Spaccapelo L, Leonardi P, Carlin A, Ottani A, Galantucci M, Grieco P, Catania A, Guarini S. Molecular changes induced in rat liver by hemorrhage and effects of melanocortin treatment. Anesthesiology. 2012 Mar;116(3):692-700. doi: 10.1097/ALN.0b013e318246ea68. PubMed PMID: 22266570. 7: Minutoli L, Squadrito F, Nicotina PA, Giuliani D, Ottani A, Polito F, Bitto A, Irrera N, Guzzo G, Spaccapelo L, Fazzari C, Macrì A, Marini H, Guarini S, Altavilla D. Melanocortin 4 receptor stimulation decreases pancreatitis severity in rats by activation of the cholinergic anti-inflammatory pathway. Crit Care Med. 2011 May;39(5):1089-96. doi: 10.1097/CCM.0b013e318207ea80. PubMed PMID: 21263321. 8: Agosti F, López Soto EJ, Cabral A, Castrogiovanni D, Schioth HB, Perelló M, Raingo J. Melanocortin 4 receptor activation inhibits presynaptic N-type calcium channels in amygdaloid complex neurons. Eur J Neurosci. 2014 Sep;40(5):2755-65. doi: 10.1111/ejn.12650. Epub 2014 Jun 18. PubMed PMID: 24943127. 9: Spaccapelo L, Bitto A, Galantucci M, Ottani A, Irrera N, Minutoli L, Altavilla D, Novellino E, Grieco P, Zaffe D, Squadrito F, Giuliani D, Guarini S. Melanocortin MC₄ receptor agonists counteract late inflammatory and apoptotic responses and improve neuronal functionality after cerebral ischemia. Eur J Pharmacol. 2011 Nov 30;670(2-3):479-86. doi: 10.1016/j.ejphar.2011.09.015. Epub 2011 Sep 21. PubMed PMID: 21946115. 10: Giuliani D, Mioni C, Bazzani C, Zaffe D, Botticelli AR, Capolongo S, Sabba A, Galantucci M, Iannone A, Grieco P, Novellino E, Colombo G, Tomasi A, Catania A, Guarini S. Selective melanocortin MC4 receptor agonists reverse haemorrhagic shock and prevent multiple organ damage. Br J Pharmacol. 2007 Mar;150(5):595-603. Epub 2007 Jan 22. PubMed PMID: 17245369; PubMed Central PMCID: PMC2189765. 11: Gomez-Sanmiguel AB, Nieto-Bona MP, Fernandez-Galaz C, Priego T, Martin AI, Lopez-Calderon A. Melanocortin-4 receptor agonist (RO27-3225) ameliorates soleus but not gastrocnemius atrophy in arthritic rats. J Physiol Pharmacol. 2017 Apr;68(2):191-199. PubMed PMID: 28614768.